Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

Herpes zoster in immunocompromised patients: incidence, timing, and risk factors.

Wung PK, Holbrook JT, Hoffman GS, Tibbs AK, Specks U, Min YI, Merkel PA, Spiera R, Davis JC, St Clair EW, McCune J, Ytterberg SR, Allen NB, Stone JH; WGET Research Group.

Am J Med. 2005 Dec;118(12):1416.

PMID:
16378799
2.

Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response.

Omdal R, Wildhagen K, Hansen T, Gunnarsson R, Kristoffersen G.

Scand J Rheumatol. 2005 May-Jun;34(3):229-32.

PMID:
16134730
4.

Rituximab is an alternative in a case of contra-indication of cyclophosphamide in Wegener's granulomatosis.

Bachmeyer C, Cadranel JF, Demontis R.

Nephrol Dial Transplant. 2005 Jun;20(6):1274. Epub 2005 Apr 19. No abstract available.

5.

Prolonged treatment of refractory Wegener's granulomatosis with 15-deoxyspergualin: an open study in seven patients.

Schmitt WH, Birck R, Heinzel PA, Göbel U, Choi M, Warnatz K, Peter HH, van der Woude FJ.

Nephrol Dial Transplant. 2005 Jun;20(6):1083-92. Epub 2005 Apr 12.

6.

Effective therapeutic use of rituximab in refractory Wegener's granulomatosis.

Ferraro AJ, Day CJ, Drayson MT, Savage CO.

Nephrol Dial Transplant. 2005 Mar;20(3):622-5. No abstract available.

7.

Etanercept plus standard therapy for Wegener's granulomatosis.

Wegener's Granulomatosis Etanercept Trial (WGET) Research Group.

N Engl J Med. 2005 Jan 27;352(4):351-61.

8.

Rituximab induced remission in a patient with Wegener's granulomatosis.

Kallenbach M, Duan H, Ring T.

Nephron Clin Pract. 2005;99(3):c92-6. Epub 2005 Jan 20.

PMID:
15665552
9.
10.

Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174.

Bearden CM, Agarwal A, Book BK, Vieira CA, Sidner RA, Ochs HD, Young M, Pescovitz MD.

Am J Transplant. 2005 Jan;5(1):50-7.

11.

Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.

Dai MS, Chao TY, Kao WY, Shyu RY, Liu TM.

Ann Hematol. 2004 Dec;83(12):769-74. Epub 2004 Aug 25.

PMID:
15338194
12.

B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.

Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I.

Arthritis Rheum. 2004 Aug;50(8):2580-9.

13.

The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy.

Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, Tedder TF.

J Exp Med. 2004 Jun 21;199(12):1659-69.

14.

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T.

N Engl J Med. 2004 Jun 17;350(25):2572-81.

15.

Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo.

Pfister H, Ollert M, Fröhlich LF, Quintanilla-Martinez L, Colby TV, Specks U, Jenne DE.

Blood. 2004 Sep 1;104(5):1411-8. Epub 2004 May 18.

16.

Pathogenic roles of B cells in human autoimmunity; insights from the clinic.

Martin F, Chan AC.

Immunity. 2004 May;20(5):517-27. Review.

17.

Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients.

Schmitt WH, Hagen EC, Neumann I, Nowack R, Flores-Suárez LF, van der Woude FJ; European Vasculitis Study Group.

Kidney Int. 2004 Apr;65(4):1440-8.

18.

Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis.

Cambridge G, Leandro MJ, Edwards JC, Ehrenstein MR, Salden M, Bodman-Smith M, Webster AD.

Arthritis Rheum. 2003 Aug;48(8):2146-54.

19.

A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.

Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniené J, Ekstrand A, Gaskin G, Gregorini G, de Groot K, Gross W, Hagen EC, Mirapeix E, Pettersson E, Siegert C, Sinico A, Tesar V, Westman K, Pusey C; European Vasculitis Study Group.

N Engl J Med. 2003 Jul 3;349(1):36-44.

20.

Rituximab in idiopathic membranous nephropathy: a one-year prospective study.

Ruggenenti P, Chiurchiu C, Brusegan V, Abbate M, Perna A, Filippi C, Remuzzi G.

J Am Soc Nephrol. 2003 Jul;14(7):1851-7.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk